Bisacodyl Suppository Use in Pediatric Constipation – Evidence‑Based Guidance

Pharmacodynamics and Mechanism

• In children aged 6 – under 12 years, rectal bisacodyl is hydrolyzed by colonic mucosal enzymes to the active metabolite BHPM, which directly stimulates colonic mucosa to increase peristalsis and fluid secretion, providing a rapid laxative effect【1】.

Onset of Action

• After a single 5 mg (half‑tablet) rectal dose in children 6 – under 12 years, bowel movements typically begin within 30–60 minutes, markedly faster than oral formulations【1】.

Indications and Clinical Use

• Guideline recommendations endorse bisacodyl suppositories as short‑term or rescue therapy for pediatric constipation when stool has not passed for ≥3 days【1】.
• The same guidelines identify bisacodyl suppositories as appropriate for acute constipation episodes lasting three days in children, aligning with rescue‑therapy use【3】.
• When conventional osmotic laxatives (e.g., polyethylene glycol, milk of magnesia) are insufficient, stimulant laxatives such as bisacodyl suppositories may be added, ideally administered ≈30 minutes after a meal to exploit the gastrocolonic response【3】.

Contraindications (Pediatric Population)

• Bisacodyl suppositories should not be used in children with any of the following: intestinal obstruction or ileus, severe dehydration, or acute inflammatory bowel disease, as these conditions increase the risk of serious adverse events【1】.

Adverse Effects

• The most common mild adverse events in children are abdominal cramping or discomfort and diarrhea; these typically arise within the first week of therapy【1】.

Guideline‑Based First‑Line Management (Pediatric Constipation)

• Current pediatric constipation guidelines recommend initiating treatment with dietary fiber supplementation and osmotic laxatives (e.g., polyethylene glycol, milk of magnesia) before considering stimulant agents like bisacodyl【3】.

Strength of evidence: All statements are derived from guideline recommendations and clinical studies published in the journal Gastroenterology (2023 & 2013), reflecting moderate‑quality evidence as reflected in the cited guidelines.